DARE - Company ID 0001401914
The table below shows Dare Bioscience, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $152.46K | $2.26K | - | $25.43K | $41.69K | $22.44K |
| Cost of revenue | $242.32K | - | - | $0.00 | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $660.46K | $1.18M | $1.43M | $2.30M | $2.68M | $4.93M |
Dare Bioscience, Inc. reported annual revenue of $1.03M for fiscal year 2025. That is up 10429.4% from $9.78K in fiscal 2024. Over the 9 fiscal years shown, annual revenue grew from $625.00K (FY 2012) to $1.03M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.25M |
| $2.50M |
| $2.38M |
| $2.31M |
| $2.04M |
| $2.45M |
| Operating income | -$3.00M | -$3.67M | -$3.83M | -$4.58M | -$4.68M | -$7.36M |
| Income tax | - | - | - | - | - | - |
| Net income | -$3.00M | -$3.56M | -$4.02M | -$4.38M | -$4.70M | $12.91M |
| EPS (diluted) | -$0.21 | -$0.28 | -$0.45 | -$0.50 | -$0.55 | $1.52 |